Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has received an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $11.50.

KLRS has been the topic of a number of analyst reports. Piper Sandler set a $3.00 target price on shares of Kalaris Therapeutics and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Citigroup initiated coverage on Kalaris Therapeutics in a report on Monday, November 3rd. They issued an “outperform” rating on the stock. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (e)” rating on shares of Kalaris Therapeutics in a report on Wednesday, October 8th. Finally, Citizens Jmp began coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price target on the stock.

Institutional Investors Weigh In On Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in KLRS. XTX Topco Ltd bought a new stake in Kalaris Therapeutics in the 2nd quarter worth $65,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics during the third quarter worth about $231,000. Finally, Belpointe Asset Management LLC bought a new stake in shares of Kalaris Therapeutics in the third quarter worth about $231,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Performance

Shares of KLRS opened at $4.75 on Monday. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $17.25. The stock has a 50 day moving average price of $5.00. The stock has a market capitalization of $88.83 million, a price-to-earnings ratio of -1.17 and a beta of 0.42.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.